The natural history of progressive fibrosing interstitial lung diseases
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
We used data from the INBUILD and INPULSIS trials to investigate the natural history of progressive fibrosing interstitial lung diseases (ILDs). Subjects in the two INPULSIS trials had a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) while subjects in the INBUILD trial had a progressive fibrosing ILD other than IPF and met protocol-defined criteria for ILD progression despite management. Using data from the placebo groups, we compared the rate of decline in forced vital capacity (FVC) (mL·year −1 ) and mortality over 52 weeks in the INBUILD trial with pooled data from the INPULSIS trials. The adjusted mean annual rate of decline in FVC in the INBUILD trial (n=331) was similar to that observed in the INPULSIS trials (n=423) (−192.9 mL·year −1 and −221.0 mL·year −1 , respectively; nominal p-value=0.19). The proportion of subjects who had a relative decline in FVC >10% predicted at Week 52 was 48.9% in the INBUILD trial and 48.7% in the INPULSIS trials, and the proportion who died over 52 weeks was 5.1% in the INBUILD trial and 7.8% in the INPULSIS trials. A relative decline in FVC >10% predicted was associated with an increased risk of death in the INBUILD trial (hazard ratio 3.64) and the INPULSIS trials (hazard ratio 3.95). These findings indicate that patients with fibrosing ILDs other than IPF, who are progressing despite management, have a subsequent clinical course similar to patients with untreated IPF, with a high risk of further ILD progression and early mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At this point, no biomarker or clinical prediction algorithm has been established as a reliable predictor for disease outcome or response to therapy in ILD.(233)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [233]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationNintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib is an intracellular inhibitor of tyrosine kinases [10, 25].”
BackgroundMechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationUsual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Kim, E. J., Elicker, B. M., Maldonado, F., Webb, W. R., Ryu, J. H., Van Uden, J. H., Lee, J. S., King, T. E., & Collard, H. R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00092309 · Cited by 587 · cited 2×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
BackgroundWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527 · cited 1×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citationPredictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388 · cited 2×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citation
Cited by
Items 201–300 of 300
Shchepikhin, E. I., Shmelev, E. I., & Эргешов, А. Э. (2024) · Ural Medical Journal · doi:10.52420/2071-5943-2024-23-1-37-45 · Cited by 1
Carroll, M. B., Elliott, D. F., Kanne, J. P., & Martin, M. D. (2024) · Advances in Clinical Radiology · doi:10.1016/j.yacr.2024.04.007 · Cited by 1
Kadushkin, A. G., Yudina, O., Lukashevich, N., Davidovskaya, Е. I., Filanyuk, V., Dziadzichkina, V. V., & Cai, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-93221-z · Cited by 2
“Moreover, the clinical course (without proper therapy) and unfavorable prognosis for mortality are similar in patients with PF-ILD and IPF 5,6 .”
Rzepka-Wrona, P., Trzaska-Sobczak, M., Barczyk, A., & Skoczyński, S. (2025) · JMIR Formative Research · doi:10.2196/64409 · Cited by 1
Gohari, N. S. F., Hoseinzadeh, F., Khalaji, A., Mirzaei, S., & Jelodar, M. G. (2025) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s561159 · Cited by 2
Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis
Mackintosh, J. A., Walsh, S. L. F., Silva, M., Calandriello, L., Humphries, S. M., Lynch, D. A., Jo, H., Glaspole, I., Grainge, C., Goh, N. S. L., et al. (2026) · Respirology · doi:10.1002/resp.70196 · Cited by 2
Self-citationProgressive pulmonary fibrosis: the importance of identification and intervention
Molyneaux, P. L., & Maher, T. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0051-2025 · Cited by 1
“…be associated with very high morbidity and mortality, was that the decline in FVC over 1 year in the placebo group of the INBUILD trial was similar to the decline observed in the placebo arms of the INPULSIS trials in patients with IPF ( − 193 mL·year − 1 and − 221 mL·year − 1 , respectively) [18].”
A syndromic framework for progressive pulmonary fibrosis
Perrotta, F., Luppi, F., Sebastiani, M., & Bianco, A. (2026) · Respiratory Research · doi:10.1186/s12931-026-03649-8 · Cited by 1
“Nevertheless, several studies reported numerical or exploratory reductions in FVC decline favouring pirfenidone, particularly in patients with documented progression [8, 76].”
InfluentialWalters, S. H., Soulard, S., Ye, W., Elsen, A., Kongnakorn, T., Raj, S. S., Pimple, P. M., Ferreira, P. G., & Froidure, A. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03601-8 · Cited by 1
Srivali, N., & Giacomi, F. D. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101492 · Cited by 1
In Vitro Assessment of Nintedanib in Keratoconus Corneal Stromal Microenvironment
Moradi, Y., Shrestha, P., Mabry, S., Sharma, P., Multani, K. S., Riaz, K. M., & Karamichos, D. (2026) · Biomolecules · doi:10.3390/biom16081137 · Cited by 1
“Clinical trials, including INPULSIS and TOMORROW trials [35,68,69], provided evidence that NIN significantly reduced the decline in forced vital capacity (FVC), which is a standard measure of lung function, compared to placebo [70].”
Kase, K., Watanabe, S., Horie, M., Muto, A., Iwasaki, K., Akasaki, K., Kobayashi, T., Arai, S., Koba, H., Yamamura, K., et al. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00123.2026 · Cited by 1
Progressive Fibrosis in Interstitial Lung Diseases—Proposed Definition and Management
Martusewicz-Boros, M. M., & Piotrowski, W. J. (2021) · Advances in respiratory medicine · doi:10.5603/arm.a2021.0103 · Cited by 1
Rehabilitation during the COVID-19 pandemic
Голота, А. С., Kamilova, Т. A., Макаренко, С. В., Sarana, А. М., & Sсherbak, S. G. (2022) · Journal of clinical practice · doi:10.17816/clinpract79364 · Cited by 1
“Это состояние влияет на качество жизни пациентов и повышает риск ранней смерти [30, 31].”
Arnaud, L., & Espinosa, G. (2022) · Technical report · doi:10.1016/b978-0-323-91083-5.00001-3 · Cited by 1
Pérez‐Romero, A. G., Barajas-Hernández, U. A., Contreras-Rodríguez, F. D. J., de Santiago, A. S., Macìas-Díaz, D. M. D. J., Díaz, J. M. G., & Ponce-Campos, S. D. (2023) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2023.101957 · Cited by 1
Yasuoka, H., Waseda, Y., Kaneko, Y., Okazaki, M., Iwasaki, R., Nagata, S., Small, M., & Ishii, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1526531 · Cited by 1
Ferreiro‐Posse, A., Granados, G. D., Salvador, S., Pilia, M. F., Espejo, D., Mesones, C. E. R., Ojanguren, Í., Muñoz, X., & Villar, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061974 · Cited by 1
The moving target of progressive pulmonary fibrosis: insights for future clinical trials
Cottin, V., Mismetti, V., Valenzuela, C., & Oldham, J. M. (2025) · European Respiratory Journal · doi:10.1183/13993003.00118-2025 · Cited by 1
Self-citationCombination Therapy in Pulmonary Fibrosis: A New Era
Luppi, F., Ferrara, G., & Vancheri, C. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.01.012 · Cited by 1
Comment on “The natural history of progressive fibrosing interstitial lung diseases”
Moodley, Y. P., Zappala, C. J., Tedja, C., Clynick, B., Tan, D. B. A., & Walters, E. H. (2020) · European Respiratory Journal · doi:10.1183/13993003.03508-2020
Kayser, C., Pereira, C., Müller, C. D. S., Sampaio-Barros, P. D., Giorgi, R. D. N., Rubin, A. S., da Costa, C. H., Storrer, K. M., Vita, M. C., & Padilha, D. M. D. H. (2021) · Congresso Brasileiro de Reumatologia · doi:10.47660/cbr.2020.16962
Bildgebung bei Fibrose und typische Befundmuster
Rehbock, B., & Hamer, O. W. (2021) · Der Pneumologe · doi:10.1007/s10405-021-00398-x
Nintedanib in the treatment of systemic rheumatic disease-associated interstitial lung disease
Zela, O. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.088
PD-L1highAT2 cells: a new player for alveoli regeneration
Fouillade, C., & Londoño‐Vallejo, A. (2021) · European Respiratory Journal · doi:10.1183/13993003.01417-2021
Cottin, V., Lega, J., Coury, F., & Nasser, M. (2022) · Revue du Rhumatisme · doi:10.1016/j.rhum.2022.03.006
Self-citation[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis
Molina‐Molina, M., Buendía-Roldán, I., Castillo, D., Caro, F. M., Valenzuela, C., & Selman, M. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.12.017 · Cited by 1
Palliative Care Support Improves Quality of Life of Patients with Advanced Interstitial Lung DiseasePreprint
Cortés-Telles, A., Martínez-Ponce, J. C., López-Pavón, L. E., & Cansino-Torres, M. A. (2022) · Research Square · doi:10.21203/rs.3.rs-1550689/v1
Biekšienė, K. (2022) · Pulmonology and allergology · doi:10.37499/pia.1024
Telini, W. M. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2022.tde-30092022-091143
Fibroses pulmonaires : mise à jour des recommandations et nouveaux traitements
Bouvry, D. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00775-3
Current views on diagnosis, treatment and prevention of occupational hypersensitivity pneumonitis
Gorblyansky, Y. Y., Ramazanova, E. R., Kontorovich, E. P., & Ponamareva, О. P. (2023) · Russian Journal of Occupational Health and Industrial Ecology · doi:10.31089/1026-9428-2023-63-3-171-178
New Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Yoo, H. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.2.64
Evolving Concepts and Controversies in Interstitial Lung diseases: Update in 2023
Wawryko, P., & Yi, E. S. (2023) · Medical Research Archives · doi:10.18103/mra.v11i8.4305
PID inclassables et PID fibrosantes progressives
Léderlin, M. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-78190-2.00010-8
WITHDRAWN: Regulation of Interstitial Lung Diseases by Pulmonary Endothelial Cells via PLVAPPreprint
Zhang, X., Jia, L., Hou, R., Zhao, Y.-A., Zhang, L., Tong, X., Mo, Y., & Zhang, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.12.584592
Autoimmune interstitial lung disease
Herrán, M., Galindo, J. L., Chaves, J. J., Carrillo-Bayona, J. A., Polo, F. C., Rojas, M., & Anaya, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00007-2
Molekulare Diagnostik der interstitiellen Lungenerkrankungen
Jonigk, D. D., Verleden, S. E., & Länger, F. P. (2024) · Springer eBooks · doi:10.1007/978-3-662-67073-6_36
Ahmad, S., Maqsood, K., Liaqat, F., & Roohi, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1463433
“Even though the virus is eliminated in patients who have recovered from the coronavirus, the elimination of the cause of pulmonary damage alone does not prevent the development of escalating, fibrotic, irreparable interstitial lung disease (4).”
Kellogg, D. L., Peters, J. I., Sherratt, J., Heraud, S. O., Dollar, F., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251342661
“33,34 Reporting 6-min walk distance is a more patient-centered endpoint although subject to confounding from comorbidities.”
The Changing Landscape of Lung Transplantation
Sadeleer, L. D., Godinas, L., Dupont, L., Ceulemans, L. J., Vos, R., & Bos, S. (2025) · Respiratory The American Medical Journal · doi:10.33590/respiramj/zkbr4615 · Cited by 2
Interstitial lung diseases: a view on the problem
Sych, O. G., Dziublyk, Y., & Liubarets, T. F. (2025) · Ukrainian Journal of Military Medicine · doi:10.46847/ujmm.2025.2(6)-024
Shchepikhin, E. I., Евдокимова, С. А., Beketova, T. V., Bаgdаsаryan, T. R., & Vladimirova, N. N. (2025) · PULMONOLOGIYA · doi:10.18093/0869-0189-2025-35-4-482-490
Bankier, A. A. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202508-1927ed
Was ist gesichert in der Therapie der interstitiellen Lungenerkrankungen?
Veit, T., & Behr, J. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-02004-1
Antifibrotics in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases
Behzadian, Y., & Lau, A. K. (2025) · Canadian Respirology Today · doi:10.58931/crt.2025.1318
Mononen, M., Saari, E., Hasala, H., Kettunen, H.-P., Suoranta, S., Nurmi, H., Kärkkäinen, M. S., Selander, T., Randell, J. T., Laurikka, J. O., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20488724
Kreuter, M., Bendstrup, E. M., Jouneau, S., Maher, T. M., Inoue, Y., Miede, C., Lievens, D., & Crestani, B. (2023) · Figshare · doi:10.6084/m9.figshare.22626086
Cottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227729
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227717
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549517
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227732
Self-citationNasser, M., Larrieu, S., Boussel, L., Si-Mohamed, S. A., Bazin, F., Marque, S., Massol, J., Thivolet-Béjui, F., Chalabreysse, L., Maucort‐Boulch, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14670499
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227711
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227714
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227741
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227720
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549511
Self-citationKwon, B. S., Choe, J., Chae, E. J., Hwang, H. S., Kim, Y.-G., & Song, J. W. (2021) · Figshare · doi:10.6084/m9.figshare.16911206
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger-Christ, K. M., Pinto-Plata, V., Liesching, T. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568460
Cottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227726
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227735
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227744
Self-citationSinger, D., Chastek, B., Sargent, A., Johnson, J. C., Shetty, S. S., Conoscenti, C., & Bernstein, E. J. (2024) · Figshare · doi:10.6084/m9.figshare.26616373
Ushio, Y., Wakiya, R., Kameda, T., Nakashima, S., Shimada, H., Miyagi, T., Sugihara, K., Mino, R., Mizusaki, M., Chujo, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26054611
Cottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549514
Self-citationGuler, S. A., Machahua, C., Geiser, T. K., Kocher, G., Marti, T. M., Tan, B., Trappetti, V., Ryerson, C. J., & Funke-Chambour, M. (2022) · Figshare · doi:10.6084/m9.figshare.20035703
Cottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549526
Self-citationLobo, L. J., Liu, Y., Li, P., Ramaswamy, M., Swaminathan, A. C., Veeraraghavan, S., Fan, Y., Neely, M. L., Palmer, S. M., & Olson, A. L. (2024) · Figshare · doi:10.6084/m9.figshare.27123989
Cottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549508
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549505
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227708
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227723
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549520
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227738
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227705
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549523
Self-citationPatel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger-Christ, K. M., Pinto-Plata, V., Liesching, T. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568463
Plachi, F. (2022) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Ito, T., Shibuya, A., & Noguchi, H. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03502-w
Management der progredienten Lungenfibrosen – Update 2025
Schlee, T., Kreuter, M., & Krönig, J. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2609-8433
“klinischen Phänotyp mit gleich hoher Mortalität wie die IPF auf-weisen können [5].”
Santos, R. F., Cardoso, C. G., Pinto, A., Oliveira, L., Coelho, D. B., Gonçalves, M., Alexandre, A. T., Melo, N. C. V., Mota, P. C., Neves, I., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03555-z
Prevalence and Prognostic Impact of Progressive Pulmonary Fibrosis
Park, J. H. (2026) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2025.0216
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04347-3
Sompalli, A. K., Pulugundla, V., Kotha, N. C. R., Kailasa, S. R., Ganguly, E., Sharma, P. K., & Ansari, M. S. S. (2026) · Journal of Association of Pulmonologist of Tamil Nadu · doi:10.4103/japt.japt_40_25
Kølner-Augustson, L., Altraja, A., Bendstrup, E. M., Bradding, P., Østergård, N. M., Wilson, A. C., Simonsen, U., & Hilberg, O. (2026) · Diagnostics · doi:10.3390/diagnostics16111649
“These cells deposit excessive extracellular matrix, leading to architectural distortion, progressive loss of lung compliance, impaired gas exchange, and ultimately respiratory failure [2,4].”
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101463
Wells, A. U. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag175
Self-citationPalliative Care Support Improves Quality of Life of Patients with Fibrotic Interstitial Lung Disease
Cortés-Telles, A., Ortíz‐Farias, D. L., Martínez-Ponce, J. C., López-Pavón, L. E., Cansino-Torres, M. A., & Ryerson, C. J. (2026) · Palliative Medicine Reports · doi:10.1177/26892820261463086
Maher, T. M., Kaminski, N., Wang, F., Funke-Chambour, M., Wu, C., Hu, Y., Sharma, S., Schafer, P. H., Schaller, M. A., & Horan, G. S. B. (2026) · Respiratory Research · doi:10.1186/s12931-026-03809-w · Cited by 1
A multidimensional index with SpO2 at rest for predicting progressive pulmonary fibrosis
Silva, S. A. E. H. C. D., Resende, A. C. L., Mancuzo, E. V., Storrer, K. M., Arantes, L. F. N., Aguiar, F., Soares, M. R., & Pereira, C. A. D. C. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250336
Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
Suzuki, Y., Yoshimura, K., Mori, K., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101510
Zhang, X., Wang, Y., & Che, P. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090951
“These diseases frequently overlap in clinical presentation: similar patterns on high-resolution computed tomography (HRCT) [11,12], comparable pulmonary function decline [13,14], and indistinguishable symptoms of progressive dyspnea and cough [2].”
Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review
Deng, Z., Karrasch, S., Alter, P., Rivera‐Ortega, P., Behr, J., & Jörres, R. A. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2026-004356
“Concerted efforts to improve early symptom recognition, standardise referral pathways and accelerate access to antifibrotic therapy are imperative to alter the trajectory of these devastating diseases.”
Are We Closer to Predicting Radiological Progression Among ILD Patients?
Li, A., & Corte, T. J. (2026) · Respirology · doi:10.1002/resp.70327
Suzuki, K., Akiyama, M., Shimanuki, K., Fukui, H., & Kaneko, Y. (2026) · Modern Rheumatology · doi:10.1093/mr/roag088
Specialized Center for interstitial lung diseases. Results and prospects
Викторович, Л. И., Михайловна, Т. Н., Glushkova, T. V., & Ponomareva, N. D. (2026) · Journal of Respiratory Medicine · doi:10.17116/respmed2026203139
Yang, M. M., Sheppard, D., & Wolters, P. J. (2026) · Thorax · doi:10.1136/thorax-2025-224689
Metadata
- Authors
- Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., & Wells, A. U.
- Affiliations
- National Jewish Health (US)
- Imperial College London (GB)
- University of Alabama at Birmingham (US)
- Medizinische Hochschule Hannover (DE)
- Boehringer Ingelheim (Germany) (DE)
- Lyon 1 Université (FR)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Corresponding author
- Brown, Kevin K.
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-03-26
- Volume
- 55
- Issue
- 6
- Pages
- 2000085
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC7315005
- OpenAlex
- W3013021754
- Semantic Scholar
- eeb975721a6bad50451a09c9b2ffa308b44a51aa
- Cited by
- 293
- References
- 35
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 46 · 2023: 41 · 2022: 66 · 2021: 62 · 2020: 12
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- progressive fibrosing interstitial lung disease, idiopathic pulmonary fibrosis, natural history (disease), forced vital capacity decline, mortality, ILD progression, INBUILD trial, INPULSIS trials
- MeSH terms
- Aged, Female, Humans, Indoles, Male, Middle Aged, Vital Capacity, Lung Diseases, Interstitial, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.